Pharming Group
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 month.
- Its last 5 Sell calls were actually followed by a +4% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -15.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 35.0x | Better than 17% |
| Forward P/E | 31.5x | Better than 17% |
| Price / Sales | 2.3x | Better than 52% |
| P/E vs own 5-yr range | 77th pctl | Better than 29% |
Growth B
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 22.3% | Better than 84% |
| Net income CAGR (3Y) | -40.7% | Better than 7% |
| Free cash flow CAGR (3Y) | 38.1% | Better than 79% |
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 87.9% | Better than 95% |
| Operating margin | 5.6% | Better than 36% |
| Net margin | 0.8% | Better than 28% |
| Return on equity | 1.1% | Better than 30% |
| Return on invested capital | 2.5% | Better than 35% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -2.6% | Better than 68% |
| 6-month return | -8.4% | Better than 42% |
| 12-month return (ex latest month) | -34.4% | Better than 7% |
| Distance below 52-week high | 45.9% | Better than 23% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.6x | Better than 68% |
| Debt to assets | 23.2% | Better than 51% |
| Interest coverage | 2.2x | Better than 38% |
| Free cash flow / net income | 1,892.4% | Better than 98% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 12.17
- Open
- 11.85
- Day range
- 11.30 - 11.97
- Avg price
- 11.75
- Volume
- 10.51K
- Turnover
- 123.40K
- Turnover ratei
- 0.02%
- Volume ratioi
- 1.29
- Amplitudei
- 5.54%
- 52-week rangei
- 9.11 - 21.34
Valuation
- P/Ei
- 288.50
- P/E (TTM)i
- 34.97
- P/Bi
- 2.80
- EPSi
- 0.04
- Book value / shi
- 4.12
- Net profit
- 2.83M
- Net assets
- 291.25M
Share structure
- Market cap
- 816.78M
- Float capi
- 803.84M
- Shares out
- 70.78M
- Float sharesi
- 69.66M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-12-23
45.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-266.56K net over the window
Short interest
- Shares short
- 25.78K
- % of floati
- 0.04%
- Days to coveri
- 1.42
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Pharming Group (PHAR)?
Pharming Group last traded at 11.54. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Pharming Group's market cap?
About 816.78M.
What is the P/E ratio of Pharming Group?
The trailing twelve-month P/E is 34.97. The Valuation tab shows it against the stock's own five-year range.
Does Pharming Group pay a dividend?
Pharming Group does not currently pay a regular dividend.
Is Pharming Group a buy according to analysts?
The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 39.00, which implies 238.0% upside from the current price. This is not investment advice.
What is Pharming Group's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Pharming Group a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:01:09 · For reference only, not investment advice and not tailored to your situation.
Pharming Group discussion 0 comments